Whitfield Advises Altaris on Acquisition of Clarivate's Life Sciences & Healthcare Business
Overview
Altaris agreed to buy Clarivate's Life Sciences & Healthcare operation for an aggregate $600 million, according to the source announcement about the business separation.
Consideration components
The reported price comprised $500 million cash at closing, $25 million deferred and a $75 million unsecured senior note, subject to adjustments.
Business perimeter
The Cortellis and Decision Resources Group portfolios would operate independently under Altaris ownership after completion.
Conditions and advisers
Closing was expected in the second half of 2026, subject to approvals. Laura Sullivan and Heath Mayo are among the corporate advisers named, with technology, finance and tax teams also credited.
Related Pages
Whitfield Advises AEVEX on Acquisition of BlackSea TechnologiesWhitfield Advises Thrive Holdings on $2 Billion FundraiseWhitfield Represents Trinity Hunt Partners on Investment in Fisher Management PartnersAustinChicagoHouston
View More (18)
Los AngelesMiamiParisBay Area – San FranciscoWashington, D.C.Technology & IP TransactionsAntitrust & CompetitionDebt FinanceEmployee BenefitsEmployment & LaborEnvironmentalExecutive CompensationHealthcare & Life Sciences TransactionsInternational Trade & National SecurityMergers & AcquisitionsReal AssetsReal EstateTax
